Literature DB >> 32343721

Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).

Dan Nakano1, Takumi Kawaguchi1, Hideki Iwamoto1,2, Masako Hayakawa2, Hironori Koga1,2, Takuji Torimura1,2.   

Abstract

AIM: Metabolic reprograming is crucial in the proliferation of hepatocellular carcinoma (HCC). Canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, affects various metabolisms. We investigated the effects of CANA on proliferation and metabolic reprograming of HCC cell lines using multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
METHODS: The cells were counted 72 hours after treatment with CANA (10 μM; n = 5) or dimethyl sulfoxide (control [CON]; n = 5) in Hep3B and Huh7 cells. In Hep3B cells, metabolomics and iMPAQT were used to evaluate the levels of metabolites and metabolic enzymes in the CANA and CON groups (each n = 5) 48 hours after treatment.
RESULTS: Seventy-two hours after treatment, the number of cells in the CANA group was significantly decreased compared to that in the CON group in Hep3B and Huh7 cells. On multi-omics analysis, there was a significant difference in the levels of 85 metabolites and 68 metabolic enzymes between the CANA and CON groups. For instance, CANA significantly downregulated ATP synthase F1 subunit alpha, a mitochondrial electron transport system protein (CON 297.28±20.63 vs. CANA 251.83±22.83 fmol/10 μg protein; P = 0.0183). CANA also significantly upregulated 3-hydroxybutyrate, a beta-oxidation metabolite (CON 530±14 vs. CANA 854±68 arbitrary units; P<0.001). Moreover, CANA significantly downregulated nucleoside diphosphate kinase 1 (CON 110.30±11.37 vs. CANA 89.14±8.39 fmol/10 μg protein; P = 0.0172).
CONCLUSIONS: We found that CANA suppressed the proliferation of HCC cells through alterations in mitochondrial oxidative phosphorylation metabolism, fatty acid metabolism, and purine and pyrimidine metabolism. Thus, CANA may suppress the proliferation of HCC by regulating metabolic reprograming.

Entities:  

Year:  2020        PMID: 32343721     DOI: 10.1371/journal.pone.0232283

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  6 in total

1.  Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy.

Authors:  Reina Sasaki-Tanaka; Toshikatsu Shibata; Mitsuhiko Moriyama; Hiroaki Okamoto; Hirofumi Kogure; Tatsuo Kanda
Journal:  J Virol       Date:  2022-08-30       Impact factor: 6.549

2.  Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells.

Authors:  Dan Nakano; Takumi Kawaguchi; Tsubasa Tsutsumi; Masako Hayakawa; Sachiyo Yoshio; Hironori Koga; Takuji Torimura
Journal:  JGH Open       Date:  2022-03-17

3.  Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.

Authors:  Michael Hendryx; Yi Dong; Jonas M Ndeke; Juhua Luo
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

4.  Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.

Authors:  Elmar Zügner; Hsiu-Chiung Yang; Petra Kotzbeck; Beate Boulgaropoulos; Harald Sourij; Sepideh Hagvall; Charles S Elmore; Russell Esterline; Sven Moosmang; Jan Oscarsson; Thomas R Pieber; Xiao-Rong Peng; Christoph Magnes
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

Review 5.  The metabolomic landscape plays a critical role in glioma oncogenesis.

Authors:  Kenta Masui; Webster K Cavenee; Paul S Mischel; Noriyuki Shibata
Journal:  Cancer Sci       Date:  2022-03-23       Impact factor: 6.518

Review 6.  Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review.

Authors:  Kristy T K Lau; Lui Ng; Jason W H Wong; Herbert H F Loong; Wendy W L Chan; Chi Ho Lee; Carlos K H Wong
Journal:  Rev Endocr Metab Disord       Date:  2021-07-17       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.